Comparative Outcomes of Rezūm Versus EchoLaser for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe.

Inclusion Criteria: Inclusion Criteria: Male patients aged 50 years or older. Diagnosis of symptomatic BPH with moderate-to-severe lower urinary tract symptoms, defined as an IPSS ≥ 12. Total prostate volume between 30 mL and 80 mL, confirmed via Transrectal Ultrasound (TRUS) or mpMRI. Presence of an enlarged, obstructing intravesical median lobe visualized via imaging or baseline cystoscopy. Peak urinary flow rate (Qmax) between 5 and 15 mL/s with a minimum voided volume of ≥ 125 mL. Exclusion Criteria: Confirmed or suspected prostate cancer (e.g., PSA \> 4.0 ng/mL without a subsequent negative prostate biopsy or MRI). History of prior surgical interventions for BPH (e.g., TURP, HOLEP, or other MISTs). Presence of urethral strictures, bladder neck contracture, or established neurogenic bladder dysfunction. Active urinary tract infection (UTI) or an episode of acute urinary retention requiring an indwelling catheter at the time of screening. Previous pelvic radiation therapy or severe pelvic trauma. Inability to safely pause anticoagulant/antiplatelet therapy per standard hospital perioperative protocols, if applicable.